Back to results
US 2024/0174753 A1Published application
Fusion proteins, pharmaceutical compositions, and therapeutic applications
AssigneeAnwita Biosciences, Inc.
InventorsZiyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
Life of this patent
Estimating the term…
Abstract
Provided herein are a fusion protein comprising an interleukin-2 domain, a programmed cell death-1 binding domain, and a half-life-extension domain; and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Claims117
A fusion protein comprising an interleukin-2 (IL-2) domain, a programmed cell death-1 (PD-1) binding domain, and a half-life-extension domain;
- wherein the IL-2 domain comprises:
- (i) a replacement of the amino acid residues from positions N29 to A50 with an IL-15 hinge fragment-containing peptide;
- (ii) an amino acid substitution at position E15, H16, D20, K32, K76, S87, N88, or I92;
- (iii) an amino acid substitution at a position from R38 to Y45;
- and/or (iv) a disulfide bond formed between two amino acid residues from positions N30 to L80.
2 more elements
Dependencies are inferred from the claim text.